MX2017012113A - Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. - Google Patents

Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.

Info

Publication number
MX2017012113A
MX2017012113A MX2017012113A MX2017012113A MX2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A MX 2017012113 A MX2017012113 A MX 2017012113A
Authority
MX
Mexico
Prior art keywords
treatment
cancer
antibody
combination
hdac inhibitor
Prior art date
Application number
MX2017012113A
Other languages
English (en)
Inventor
Goodenow Robert
Ordentlich Peter
Original Assignee
Syndax Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc filed Critical Syndax Pharmaceuticals Inc
Publication of MX2017012113A publication Critical patent/MX2017012113A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se describen métodos para el tratamiento de cáncer en un sujeto; en particular, se proporcionan métodos para el tratamiento de cáncer pulmonar de cólulas no pequeñas y melanoma con una combinación de entinostat y un anticuerpo anti-PD-1 o un anti-PD-L1.
MX2017012113A 2015-03-20 2016-03-18 Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer. MX2017012113A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136303P 2015-03-20 2015-03-20
US201562137601P 2015-03-24 2015-03-24
PCT/US2016/023298 WO2016154068A1 (en) 2015-03-20 2016-03-18 Combination of hdac inhibitor and anti-pd-1 antibody for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2017012113A true MX2017012113A (es) 2018-07-06

Family

ID=56977796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012113A MX2017012113A (es) 2015-03-20 2016-03-18 Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.

Country Status (12)

Country Link
US (2) US11324822B2 (es)
EP (1) EP3270966B1 (es)
JP (2) JP2018508593A (es)
KR (1) KR20170124604A (es)
CN (1) CN107614011A (es)
AU (2) AU2016235434B2 (es)
BR (1) BR112017020002A2 (es)
CA (1) CA2980297A1 (es)
HK (1) HK1250142A1 (es)
IL (2) IL307850A (es)
MX (1) MX2017012113A (es)
WO (1) WO2016154068A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3345002A4 (en) * 2015-09-02 2019-05-08 Syndax Pharmaceuticals Inc. SELECTION OF PATIENTS FOR POLYTHERAPY
WO2017120204A2 (en) * 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of histone deacetylase inhibitor and immunotherapy
AU2017211383A1 (en) 2016-01-28 2018-08-16 Indiana University Research & Technology Corporation Use of histone deacetylase inhibitors for enhancing immunotherapies
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2018098168A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof
MA50070A (fr) * 2017-09-08 2020-07-15 4Sc Ag Inhibiteur de l'histone désacétylase en association avec un modulateur de point de contrôle immunitaire pour la cancérothérapie
US20210024633A1 (en) 2018-03-28 2021-01-28 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
KR20210005950A (ko) 2018-05-07 2021-01-15 신닥스 파마슈티컬스, 인크. 병용 요법을 위한 환자의 선정
AU2019285641A1 (en) * 2018-06-15 2021-04-08 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
TW202128224A (zh) * 2019-12-23 2021-08-01 大陸商信達生物製藥（蘇州）有限公司 抗ｐｄ－１抗體和組蛋白去乙醯化酶抑制劑的藥物組合及其用途、使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US20130150386A1 (en) * 2011-12-09 2013-06-13 Syndax Pharmaceuticals, Inc. Methods for the treatment of lung cancer
US8987067B2 (en) * 2013-03-01 2015-03-24 International Business Machines Corporation Segmented guard ring structures with electrically insulated gap structures and design structures thereof
CA2917858A1 (en) 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
US9987258B2 (en) * 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
CN114099686B (zh) * 2014-07-15 2024-04-16 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
UY36351A (es) * 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
JP2018519335A (ja) * 2015-06-29 2018-07-19 シンダックス ファーマシューティカルズ， インコーポレイテッド がんの処置のためのｈｄａｃ阻害剤および抗ｐｄ−ｌ１抗体の組合せ
EP3345002A4 (en) * 2015-09-02 2019-05-08 Syndax Pharmaceuticals Inc. SELECTION OF PATIENTS FOR POLYTHERAPY

Also Published As

Publication number Publication date
RU2017134315A3 (es) 2019-09-12
CA2980297A1 (en) 2016-09-29
US20180078639A1 (en) 2018-03-22
IL254529A0 (en) 2017-11-30
KR20170124604A (ko) 2017-11-10
BR112017020002A2 (pt) 2018-06-19
AU2016235434A1 (en) 2017-10-12
EP3270966A4 (en) 2018-10-17
US11324822B2 (en) 2022-05-10
AU2016235434B2 (en) 2022-02-03
WO2016154068A1 (en) 2016-09-29
RU2017134315A (ru) 2019-04-03
EP3270966B1 (en) 2024-05-01
EP3270966A1 (en) 2018-01-24
IL254529B2 (en) 2024-05-01
US20230022573A1 (en) 2023-01-26
HK1250142A1 (zh) 2018-11-30
JP2021175754A (ja) 2021-11-04
CN107614011A (zh) 2018-01-19
JP2018508593A (ja) 2018-03-29
IL254529B1 (en) 2024-01-01
IL307850A (en) 2023-12-01
AU2022202954A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
MX2017012113A (es) Combinacion de inhibidor de histona desacetilasa y anticuerpo anti-muerte celular programada-1 para el tratamiento de cancer.
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
PH12017500322A1 (en) Anti-her2 antibodies and immunoconjugates
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
WO2016062722A8 (en) Combination
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
MX2018001398A (es) Anticuerpos monoclonales contra bcma.
MX2018008008A (es) Combinacion del inhibidor hdac y anticuerpo-pd-l1 para el tratamiento de cancer ovarico.
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX2017005888A (es) Dispositivos, sistemas y metodos para la deteccion de analitos.
HK1243439A1 (zh) Pcsk9抗體、其抗原結合片段及其醫藥用途
MX2015010789A (es) Anticuerpos anti-pcsm.
GEU20171919Y (en) Gel for electrotherapy
NZ744340A (en) Anti-jagged1 antibodies and methods of use